Hormonal
Adverse environmental conditions during early somatic development (fetal/infancy) increase the lifelong risk of chronic diseases such as obesity, diabetes, and cardiovascular disease through persistent metabolic and physiological programming.
Your health trajectory is influenced by your early environment, not just your current habits. While you cannot change your birth weight or early nutrition, understanding this link helps explain why certain metabolic risks exist and underscores the importance of maintaining a healthy lifestyle to counteract early programming.
Recent studies demonstrate associations between aggressions suffered during the initial phases of somatic development and amplified risk of chronic diseases throughout life, such as obesity, diabetes and cardiovascular diseases.
Why this rating
The paper is a non-systematic review citing observational epidemiological studies and animal models; it does not present new primary clinical trial data.
Source
Developmental origins of health and disease (DOHaD)
Patrí et al. · Jornal de Pediatria · 2007
DOI 10.2223/jped.1728
More from this paper
- Rapid postnatal weight gain ('catch-up growth') in low-birth-weight infants significantly increases the risk of developing cardiovascular disease and metabolic syndrome in adulthood.Moderate
- Breastfeeding is associated with a lower incidence of obesity and better long-term metabolic profiles (e.g., lipid levels, blood pressure) compared to formula feeding.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →